Latest Penthrox News

Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.

Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.

Medical Developments International (MVP) reported an 8% revenue increase driven by strong Penthrox growth, despite a slight EBIT loss impacted by foreign exchange. The company advances pediatric approvals and targets further volume gains.

Medical Developments International has posted positive operating cashflow for the first half of FY26, driven by robust growth in its flagship product Penthrox across Australia and Europe, alongside progress in paediatric approvals.

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.

Medical Developments International has reported a remarkable turnaround in FY25, posting a net profit after tax and securing paediatric approval for its flagship product Penthrox in Europe.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.

Medical Developments International reports a strong FY25 with significant margin gains and strategic progress, setting the stage for accelerated Penthrox expansion in FY26.

Medical Developments International (MVP) reports positive operating cash flow in H2 FY25, driven by strong Penthrox sales and strategic distribution shifts in Europe. The company eyes further growth amid regulatory progress and efficiency gains.

Medical Developments International reported a robust Q3 FY25 with $8.9 million revenue and $1.7 million operating cashflow, driven by strong Penthrox demand and pricing. New distribution agreements in France and Switzerland position the company for further European expansion.

Medical Developments International has posted a robust improvement in operating cash flow and revenue for Q2 FY25, driven by higher demand and pricing for its flagship product Penthrox across Australia and Europe.